The Intravascular Oxygenator, IVOX®: Augmentation of Blood-Gas Transfer

Wenger, Robert K.; Jd, Mortensen

doi:10.1007/978-1-4612-2484-6_30

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intracorporeal oxygenators were developed for placement within the venous system (Figure 1) to provide temporary and partial augmentation of gas transfer, but none of these devices was intended for nonreversible pulmonary failure 12 . Mortensen et al (CardioPulmonics, Inc, Salt Lake City, UT, USA) developed IVOX, the only intravascular oxygenator that has undergone phase I and II human clinical trials 11,13‐15 . Evidence was provided for intracorporeal gas exchange 11 and successful extended use of intravascular gas exchanger over 29 days was reported 16 .…”

Section: Introductionmentioning

confidence: 99%

Artificial lungs––Where are we going with the lung replacement therapy?

et al. 2020

View full text Add to dashboard Cite

Lung transplantation may be a final destination therapy in lung failure, but limited donor organ availability creates a need for alternative management, including artificial lung technology. This invited review discusses ongoing developments and future research pathways for respiratory assist devices and tissue engineering to treat advanced and refractory lung disease. An overview is also given on the aftermath of the coronavirus disease 2019 pandemic and lessons learned as the world comes out of this situation. The first order of business in the future of lung support is solving the problems with existing mechanical devices. Interestingly, challenges identified during the early days of development persist today. These challenges include device‐related infection, bleeding, thrombosis, cost, and patient quality of life. The main approaches of the future directions are to repair, restore, replace, or regenerate the lungs. Engineering improvements to hollow fiber membrane gas exchangers are enabling longer term wearable systems and can be used to bridge lung failure patients to transplantation. Progress in the development of microchannel‐based devices has provided the concept of biomimetic devices that may even enable intracorporeal implantation. Tissue engineering and cell‐based technologies have provided the concept of bioartificial lungs with properties similar to the native organ. Recent progress in artificial lung technologies includes continued advances in both engineering and biology. The final goal is to achieve a truly implantable and durable artificial lung that is applicable to destination therapy.

show abstract